半乳糖血症的实验室诊断:美国医学遗传学与基因组学学会(ACMG)技术标准与指南
该文件为美国医学遗传学与基因组学学会(ACMG)发布的技术标准与指南,主要作为临床实验室遗传学家的教育资源。半乳糖血症是Leloir通路三种酶(半乳糖-1-磷酸尿苷酰转移酶、半乳糖激酶、UDP-半乳糖-4'-差向异构酶)缺陷导致的遗传性半乳糖代谢障碍。经典型半乳糖血症(半乳糖-1-磷酸尿苷酰转移酶缺陷)是三种酶缺陷中最常见且最严重的类型,特征为生长发育迟缓、肝衰竭、脓毒症易感和死亡(如不治疗)。美国已全面实施经典型半乳糖血症新生儿筛查,而半乳糖激酶缺陷和UDP-半乳糖-4'-差向异构酶缺陷筛查尚未普及。早期识别和治疗半乳糖血症可改善结局。文件回顾了半乳糖血症诊断的实验室方法和最佳实践。
要点
- 经典型半乳糖血症由半乳糖-1-磷酸尿苷酰转移酶缺陷引起,是三种Leloir通路酶缺陷中最常见且最严重的类型。
- 未治疗的经典型半乳糖血症特征包括生长发育迟缓、肝衰竭、脓毒症易感和死亡。
- 美国已全面实施经典型半乳糖血症新生儿筛查,半乳糖激酶缺陷和UDP-半乳糖-4'-差向异构酶缺陷筛查尚未普及。
- 早期识别和治疗半乳糖血症可改善结局。
- 该文件为ACMG技术标准与指南,主要作为临床实验室遗传学家的教育资源,遵循为自愿性质。
适用人群与场景
- 半乳糖血症疑似患者,涉及Leloir通路三种酶缺陷:半乳糖-1-磷酸尿苷酰转移酶、半乳糖激酶、UDP-半乳糖-4'-差向异构酶。
- 经典型半乳糖血症(半乳糖-1-磷酸尿苷酰转移酶缺陷)为最常见且最严重的类型。
研究设计与关键结果
- 制定机构:美国医学遗传学与基因组学学会(ACMG);方法:技术标准与指南,主要作为临床实验室遗传学家的教育资源;证据分级体系:原文未报告。
- 经典型半乳糖血症(半乳糖-1-磷酸尿苷酰转移酶缺陷)是三种酶缺陷中最常见且最严重的类型,特征为生长发育迟缓、肝衰竭、脓毒症易感和死亡(如不治疗)。
- 美国已全面实施经典型半乳糖血症新生儿筛查,半乳糖激酶缺陷和UDP-半乳糖-4'-差向异构酶缺陷筛查尚未普及。
- 早期识别和治疗半乳糖血症可改善结局。
证据类型、等级与局限
- 证据类型:指南(美国医学遗传学与基因组学学会技术标准与指南);推荐强度:原文未给出等级标签;局限:原文未报告局限性。
对床旁实践的改变
- 该指南为临床实验室遗传学家提供半乳糖血症实验室诊断的方法和最佳实践,遵循为自愿性质,不保证医疗结局成功。
- 临床实验室遗传学家在决定具体操作或检测时应结合患者或标本的具体情况运用专业判断,并鼓励在患者记录中记录使用特定操作或检测的理由。
- 应注意指南采纳日期,并考虑此后出现的其他相关医学和科学信息;还应考虑知识产权利益是否可能限制某些检测和操作的实施。
指南或共识出处
- 美国医学遗传学与基因组学学会(ACMG)技术标准与指南:半乳糖血症的实验室诊断(Laboratory diagnosis of galactosemia: a technical standard and guideline of the American College of Medical Genetics and Genomics (ACMG)),发表于Genet Med。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Disclaimer: These ACMG Standards and Guidelines are developed primarily as an educational resource for clinical laboratory geneticists to help them provide quality clinical laboratory genetic services. Adherence to these Standards and Guidelines is voluntary and does not necessarily assure a successful medical outcome. These Standards and Guidelines should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the clinical laboratory geneticist should apply his or her own professional judgment to the specific circumstances presented by the individual patient or specimen. Clinical laboratory geneticists are encouraged to document in the patient's record the rationale for the use of a particular procedure or test, whether or not it is in conformance with these Standards and Guidelines. They also are advised to take notice of the date any particular guideline was adopted, and to consider other relevant medical and scientific information that becomes available after that date. It also would be prudent to consider whether intellectual property interests may restrict the performance of certain tests and other procedures.Galactosemias are inherited disorders of galactose metabolism due to deficiency in one of the three enzymes involved in the Leloir pathway: galactose-1-phosphate uridyltransferase, galactokinase, and uridine diphosphate (UDP)-galactose-4'-epimerase. Galactose-1-phosphate uridyltransferase deficiency, or classic galactosemia, is the most frequent and the most severe of the three enzyme deficiencies; it is characterized by failure to thrive, liver failure, susceptibility to sepsis, and death, if untreated. Newborn screening for classic galactosemia has been implemented in all of the United States, while screening for galactokinase deficiency and UDP-galactose-4'-epimerase deficiency is not universal. Early identification and treatment of galactosemia leads to improved outcome. This document reviews the laboratory methods and best practices for the diagnosis of galactosemia.
参考来源
- Pasquali M, Yu C, Coffee B, et al. Laboratory diagnosis of galactosemia: a technical standard and guideline of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2017. PMID: 29261178. doi:10.1038/gim.2017.172
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。